Follow The Filings

LRMR Larimar Therapeutics Inc.

Health Care, filed as LARIMAR THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 1.2%
  • $6.1M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Larimar Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.2% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 1.2%

Who owns LRMR

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 1.2%, was 2.1% Reduce −1.0% 2,008,164 $6.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by LRMR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LRMR insider trades
  • $25.7M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Thomas Edward Hamilton Director
    Buy
    $167K 50,000 shares at $3.34 +7.5% to stake
    Traded Jul 6 Filed Jul 8
    ↗
  2. James E Flynn Director, +9 joint filers
    Buy
    $25M 5,000,000 shares at $5.00 +414% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  3. Thomas Edward Hamilton Director
    Buy
    $500K 100,000 shares at $5.00 +18% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  4. Frank E Thomas Director
    Buy
    $25K 5,000 shares at $5.00 +250% to stake
    Traded Feb 27 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 3.02,5.03,9.01 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
8-K 3.02,5.03,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$36.95M -$80.6M -$165.67M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $90.18M $195.3M $142.02M
Total non-current assets * $5.76M $4.92M $3.82M
Total assets $95.94M $200.22M $145.84M
Total current liabilities $9.51M $24.36M $64.8M
Total non-current liabilities * $4.71M $4.06M $2.96M
Total equity $81.72M $171.81M $78.08M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$33.46M -$70.76M -$113.2M
Cash from investing $33.35M -$85.39M $100.31M
Cash from financing $0.03M $161.88M $65.09M
Net change in cash -$0.076M $5.74M $52.19M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.